III Actualización del Consenso de la Sociedad Española de Reumatología sobre terapia biológica en la artritis reumatoide

Carmona, 2001, The burden of musculoskeletal diseases in the general population of Spain: results from a national survey, Ann Rheum Dis, 60, 1040, 10.1136/ard.60.11.1040 Lard, 2001, Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies, Am J Med, 111, 446, 10.1016/S0002-9343(01)00872-5 Nell, 2004, Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with very early rheumatoid arthritis, Rheumatolology, 43, 906, 10.1093/rheumatology/keh199 Rodríguez-Valverde, 2004, Segunda actualización del Consenso de la Sociedad Española de Reumatología sobre la Terapia Biológica en la Artritis Reumatoide, Rev Esp Reumatol, 31, 394 Weinblatt, 1999, A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate, N Engl J Med, 340, 253, 10.1056/NEJM199901283400401 Lipsky, 2000, Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group, N Engl J Med, 343, 1594, 10.1056/NEJM200011303432202 Weinblatt, 2003, Adalimumab, a fully Human anti-tumor necrosis factor monoclonal antibody for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate. The ARMADA trial, Arthritis Rheum, 48, 35, 10.1002/art.10697 Bathon, 2000, A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis, N Engl J Med, 343, 1586, 10.1056/NEJM200011303432201 St.Clair, 2004, Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized controlled trial, Arthritis Rheum, 50, 3432, 10.1002/art.20568 Breedveld, 2004, Arthritis Rheum, 54, 26, 10.1002/art.21519 Van der Heijde, 2006, Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial, Arthritis Rheum, 54, 1063, 10.1002/art.21655 Kalden, 2005, Use of combination of leflunomide with biological agents in treatment of rheumatoid arthritis, J Rheumatol, 32, 1620 Cohen, 2002, Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: Results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial, Arthritis Rheum, 46, 614, 10.1002/art.10141 Fitzgerald, 2005, Rapid responses to anakinra in patients with refractory adult-onset Still's disease, Arthritis Rheum, 52, 1794, 10.1002/art.21061 Dinarello, 2005, Blocking IL-1 in systemic inflammation, J Exp Med, 201, 1355, 10.1084/jem.20050640 Edwards, 2004, Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis, N Engl J Med, 350, 2572, 10.1056/NEJMoa032534 Kremer, 2005, Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial, Arthritis Rheum, 52, 2263, 10.1002/art.21201 Higashida, 2005, Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatment, J Rheumatol, 32, 2109 Genovese, 2005, Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition, N Engl J Med, 353, 1114, 10.1056/NEJMoa050524 Esteve-Vives, 1993, Spanish version of the Health Assessment Questionnaire (HAQ): reliability, validity and transcultural equivalency, J Rheumatol, 20, 2116 Batlle-Gualda, 2002, Calidad de vida en la artritis reumatoide, Rev Esp Reumatol, 9 Van der Heijde, 1999, Reliability and sensitivity to change of a simplification of the Sharp/van der Heijde radiological assessment in rheumatoid arthritis, Rheumatology, 38, 941, 10.1093/rheumatology/38.10.941 Prevoo, 1995, Modified disease activity scores that include twenty-eight-joint counts, Arthritis Rheum, 38, 44, 10.1002/art.1780380107 Quinn, 2001, The therapeutic approach of early intervention for rheumatoid arthritis: what is the evidence?, Rheumatology, 40, 1211, 10.1093/rheumatology/40.11.1211 Boers, 2003, Understanding the window of opportunity concept in early rheumatoid arthritis (review), Arhritis Rheum, 48, 1771, 10.1002/art.11156 Grigor, 2004, Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial, Lancet, 364, 263, 10.1016/S0140-6736(04)16676-2 Goekoop-Ruiterman, 2005, Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial, Arthritis Rheum, 52, 3381, 10.1002/art.21405 Smolen, 2006, Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab, Arthritis Rheum, 54, 702, 10.1002/art.21678 Brocq, 2002, Etanercept - infliximab switch in rheumatoid arthritis 14 out of 131 patients treated with anti TNF. alpha, Presse Med, 31, 1836 Hansen, 2004, The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis, J Rheumatol, 31, 1098 Vollenhoven, 2001, Dose escalation of infliximab in clinical practice: Data from the Stockholm TNF registry, Arthritis Rheum, 44, S82 Oniankitan, 2004, Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C, J Rheumatol, 31, 107 Esteve, 2004, Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis, Gut, 53, 1363, 10.1136/gut.2004.040675 Peterson, 2003, Effect of tumor necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection, Ann Rheum Dis, 62, 1078, 10.1136/ard.62.11.1078 Zein, 2005, Etanercept Study Group Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study, J Hepatol, 42, 315, 10.1016/j.jhep.2004.11.025 Ellerin, 2003, Infections and anti-tumor necrosis factor therapy, Arthritis Rheum, 48, 3013, 10.1002/art.11301 Elkayam, 2004, The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis, Semin Arthritis Rheum, 33, 283, 10.1053/j.semarthrit.2003.10.003 Carmona, 2005, Registro español de acontecimientos adversos en enfermedades reumáticas (BIOBADASER). Informe de la situación a 14 Enero 2005, Reumatol Clin, 1, 95, 10.1016/S1699-258X(05)72722-4 Listín, 2005, Infections in patients with rheumatoid arthritis treated with biologic agents, Arthritis Rheum, 52, 3403, 10.1002/art.21386 Keane, 2001, Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent, N Engl J Med, 345, 1098, 10.1056/NEJMoa011110 Gomez-Reino, 2003, An active surveillance of rheumatoid arthritis patients treated with tumor necrosis factor inhibitors indicates significant tuberculosis risk increase, Arthritis Rheum, 48, 2122, 10.1002/art.11137 1992, Consenso nacional para el control de la tuberculosis en España, Med Clin (Barc), 98, 24 2002, Recomendaciones SEPAR. Normativa sobre la prevención de la tuberculosis, Arch Bronconeumol, 38, 441, 10.1016/S0300-2896(02)75259-9 2000, Targeted tuberculin testing and treatment of latent tuberculosis infection, Am J Respir Crit Care Med, 161, S221-S247 Carmona, 2005, Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists, Arthritis Rheum, 52, 1766, 10.1002/art.21043 Wallis, 2004, Granulomatous infectious diseases associated with tumor necrosis factor antagonists, Clin Infect Dis, 38, 1261, 10.1086/383317 Slifman, 2003, Listeria monocytogenes infection as a complication of treatment with anti tumor necrosis factor α-neutralizing agents, Arthritis Rheum, 48, 319, 10.1002/art.10758 Warris, 2001, Invasive pulmonary aspergillosis associated with infliximab therapy, N Eng J Med, 344, 1099, 10.1056/NEJM200104053441415 Lee, 2002, Life-threatening histoplasmosis complicating immunotherapy with tumor nerosis factor α antagonists infliximab and etanercept, Arthritis Rheum, 46, 2565, 10.1002/art.10583 Bergstrom, 2002, Coccidiomycosis (valley fever) occurring during infliximab therapy, Arthritis Rheum, 46, S169 Joven, 2005, Pregnancy in women receiving anti-TNF-alpha therapy. Experience in Spain, Arthritis Rheum, 49, S884 Antoni, 2001, Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease or rheumatoid arthritis, Artrhitis Rheum, 44, S152 Mohan, 2001, Demyelination occurring during anti-tumor necrosis factor a therapy for infflammatory arthritides, Arthritis Rheum, 44, 2862, 10.1002/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W Wolfe, 2004, Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients, Arthritis Rheum, 50, 1740, 10.1002/art.20311 Geborek, 2005, Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas, Ann Rheum Dis, 64, 699, 10.1136/ard.2004.030528 Hyrich, 2004, Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety, Ann Rheum Dis, 63, 1538, 10.1136/ard.2004.024737 Kimby, 2005, Tolerability and safety of rituximab (MabThera), Cancer Treat Rev, 31, 456, 10.1016/j.ctrv.2005.05.007